133 related articles for article (PubMed ID: 38869105)
1. Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report.
Gholizadeh Ghozloujeh Z; Srinivasan V; Al Jurdi A; Abdipour A; Norouzi S
J Investig Med High Impact Case Rep; 2024; 12():23247096241260964. PubMed ID: 38869105
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
3. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
4. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
Ismail G; Obrişcă B; Jurubiţă R; Andronesi A; Sorohan B; Vornicu A; Sinescu I; Hârza M
Medicine (Baltimore); 2020 Jun; 99(26):e21000. PubMed ID: 32590815
[TBL] [Abstract][Full Text] [Related]
5. An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.
Obrișcă B; Vornicu A; Mocanu V; Dimofte G; Andronesi A; Bobeică R; Jurubiță R; Sorohan B; Caceaune N; Ismail G
Sci Rep; 2023 Nov; 13(1):20119. PubMed ID: 37978255
[TBL] [Abstract][Full Text] [Related]
6. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
Nagy J; Sági B; Máté J; Vas T; Kovács T
Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
[TBL] [Abstract][Full Text] [Related]
8. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.
Smerud HK; Bárány P; Lindström K; Fernström A; Sandell A; Påhlsson P; Fellström B
Nephrol Dial Transplant; 2011 Oct; 26(10):3237-42. PubMed ID: 21378156
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
[TBL] [Abstract][Full Text] [Related]
10. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
[TBL] [Abstract][Full Text] [Related]
11. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response to Intestine-targeted Steroid Therapy in Biopsy-proven Immunoglobulin A Nephropathy.
Lingaraj U; Mallapur S; Viswanathan A; Vankalakunti M
Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):755-760. PubMed ID: 38018717
[TBL] [Abstract][Full Text] [Related]
14. An update on corticosteroid treatment for IgA nephropathy.
Ghaddar M; Barratt J; Barbour SJ
Curr Opin Nephrol Hypertens; 2023 May; 32(3):263-270. PubMed ID: 36866805
[TBL] [Abstract][Full Text] [Related]
15. A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.
Antonucci L; Colucci M; Emma F; Vivarelli M
Pediatr Nephrol; 2023 Nov; 38(11):3849-3852. PubMed ID: 37041389
[TBL] [Abstract][Full Text] [Related]
16. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M
J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961
[TBL] [Abstract][Full Text] [Related]
17. An update on the treatment of IgA nephropathy.
Barbour S; Feehally J
Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):319-326. PubMed ID: 28399021
[TBL] [Abstract][Full Text] [Related]
18. Reduction in proteinuria after immunosuppressive therapy and long-term kidney outcomes in patients with immunoglobulin A nephropathy.
Kang SC; Kim HW; Chang TI; Kang EW; Lim BJ; Park JT; Yoo TH; Jeong HJ; Kang SW; Han SH
Korean J Intern Med; 2021 Sep; 36(5):1169-1180. PubMed ID: 33561333
[TBL] [Abstract][Full Text] [Related]
19. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S
J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619
[TBL] [Abstract][Full Text] [Related]
20. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
